Pharmacokinetics of a loading dose of amikacin in septic patients undergoing continuous renal replacement therapy

International Journal of Antimicrobial Agents

Volumn 37, Issue 6, 2011, Pages 531-535

  Taccone, Fabio Silvio ^a   De Backer, Daniel ^a   Laterre, Pierre Franois ^b   Spapen, Herbert ^c   Dugernier, Thierry ^d   Delattre, Isabelle ^b   Wallemacq, Pierre ^b   Vincent, Jean Louis ^a   Jacobs, Frédérique ^a  

^a ERASME HOSPITAL   (Belgium)

^b CLINIQUES UNIVERSITAIRES SAINT LUC   (Belgium)

^c UZ Brussels ^*  (Belgium)

^d Clinique Saint Pierre of Ottignies   (Belgium)

Author keywords

Amikacin; Continuous renal replacement therapy; Pharmacokinetics; Sepsis

Indexed keywords

AMIKACIN; BETA LACTAM ANTIBIOTIC;

ADULT; AGED; ANTIBIOTIC SENSITIVITY; ARTICLE; CLINICAL ARTICLE; CONTINUOUS RENAL REPLACEMENT THERAPY; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DISTRIBUTION; DRUG ELIMINATION; DRUG HALF LIFE; ENTEROBACTERIACEAE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMAN; LOADING DRUG DOSE; MALE; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; NEPHROTOXICITY; PRIORITY JOURNAL; PSEUDOMONAS AERUGINOSA; SEPTIC SHOCK;

ADULT; AGED; AGED, 80 AND OVER; AMIKACIN; ANTI-BACTERIAL AGENTS; ENTEROBACTERIACEAE; FEMALE; FLUORESCENCE POLARIZATION IMMUNOASSAY; HUMANS; MALE; METABOLIC CLEARANCE RATE; MICROBIAL SENSITIVITY TESTS; MIDDLE AGED; PLASMA; PSEUDOMONAS AERUGINOSA; RENAL REPLACEMENT THERAPY; SHOCK, SEPTIC;

EID: 79955482956     PISSN: 09248579     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ijantimicag.2011.01.026     Document Type: Article

References (31)

1. R.P. Dellinger, M.M. Levy, J.M. Carlet, J. Bion, M.M. Parker, and R. Jaeschke Surviving Sepsis Campaign: international guidelines for management of severe sepsis and septic shock: 2008 Crit Care Med 36 2008 296 327
2. F.S. Taccone, P.F. Laterre, T. Dugernier, H. Spapen, I. Delattre, and X. Wittebole Insufficient β-lactam concentrations in the early phase of severe sepsis and septic shock Crit Care 14 2010 R126
3. F.S. Taccone, P.F. Laterre, H. Spapen, T. Dugernier, I. Delattre, and B. Layeux Revisiting the loading dose of amikacin for patients with severe sepsis and septic shock Crit Care 14 2010 R53
4. J.A. Roberts, and J. Lipman Pharmacokinetic issues for antibiotics in the critically ill patient Crit Care Med 37 2009 840 851
5. C. Ronco Continuous renal replacement therapies for the treatment of acute renal failure in intensive care patients Clin Nephrol 40 1993 187 198 (Pubitemid 23296964)
6. C. Ronco, C. Tetta, F. Mariano, M.L. Wratten, M. Bonello, and V. Bordoni Interpreting the mechanisms of continuous renal replacement therapy in sepsis: the peak concentration hypothesis Artif Organs 27 2003 792 801 (Pubitemid 37108619)
7. R.L. Trotman, J.C. Williamson, D.M. Shoemaker, and W.L. Salzer Antibiotic dosing in critically ill adult patients receiving continuous renal replacement therapy Clin Infect Dis 41 2005 1159 1166 (Pubitemid 41429480)
8. N. Safdar, J. Handelsman, and D.G. Maki Does combination antimicrobial therapy reduce mortality in Gram-negative bacteraemia? A meta-analysis Lancet Infect Dis 4 2004 519 527 (Pubitemid 39077923)
9. M. Paul, I. Silbiger, S. Grozinsky, K. Soares-Weiser, and L. Leibovici β Lactam antibiotic monotherapy versus β lactam-aminoglycoside antibiotic combination therapy for sepsis Cochrane Database Syst Rev 2006 CD003344
10. R.D. Moore, P.S. Lietman, and C.R. Smith Clinical response to aminoglycoside therapy: importance of the ratio of peak concentration to minimal inhibitory concentration J Infect Dis 155 1987 93 99 (Pubitemid 17225088)
11. A.D. Kashuba, A.N. Nafziger, G.L. Drusano, and J.S. Bertino Jr. Optimizing aminoglycoside therapy for nosocomial pneumonia caused by Gram-negative bacteria Antimicrob Agents Chemother 43 1999 623 629 (Pubitemid 29109529)
12. H. Mattie, W.A. Craig, and J.C. Pechere Determinants of efficacy and toxicity of aminoglycosides J Antimicrob Chemother 24 1989 281 293 (Pubitemid 19238291)
13. C. Bartal, A. Danon, F. Schlaeffer, K. Reisenberg, M. Alkan, and R. Smoliakov Pharmacokinetic dosing of aminoglycosides: a controlled trial Am J Med 114 2003 194 198 (Pubitemid 36294004)
14. P.E. Marik, I. Havlik, F.S. Monteagudo, and J. Lipman The pharmacokinetic of amikacin in critically ill adult and paediatric patients: comparison of once- versus twice-daily dosing regimens J Antimicrob Chemother 27 Suppl. C 1991 81 89
15. R. Garraffo, H.B. Drugeon, P. Dellamonica, E. Bernard, and P. Lapalus Determination of optimal dosage regimen for amikacin in healthy volunteers by study of pharmacokinetics and bactericidal activity Antimicrob Agents Chemother 34 1990 614 621 (Pubitemid 20122292)
16. A. Abbo, Y. Carmeli, S. Navon-Venezia, Y. Siegman-Igra, and M.J. Schwaber Impact of multi-drug-resistant Acinetobacter baumannii on clinical outcomes Eur J Clin Microbiol Infect Dis 26 2007 793 800 (Pubitemid 47573383)
17. J. Van Eldere Multicentre surveillance of Pseudomonas aeruginosa susceptibility patterns in nosocomial infections J Antimicrob Chemother 51 2003 347 352 (Pubitemid 36231155)
18. R.S. Rea, B. Capitano, R. Bies, K.L. Bigos, R. Smith, and H. Lee Suboptimal aminoglycoside dosing in critically ill patients Ther Drug Monit 30 2008 674 681
19. J. Plantier, A.W. Forrey, M.A. O'Neill, A.D. Blair, T.G. Christopher, and R.E. Cutler Pharmacokinetics of amikacin in patients with normal or impaired renal function: radioenzymatic acetylation assay J Infect Dis 134 Suppl. 1976 S323 S330
20. J.M. Lanao, A. Dominguez-Gil, J.M. Tabernero, and J.F. Macias Influence of type of dialyzer on the pharmacokinetics of amikacin Int J Clin Pharmacol Ther Toxicol 21 1983 197 202 (Pubitemid 13112267)
21. R. van Dalen, and T.B. Vree Pharmacokinetics of antibiotics in critically ill patients Intensive Care Med 16 Suppl. 3 1990 S235 S238
22. D.K. Armstrong, T. Hodgman, J.A. Visconti, T.E. Reilley, W.L. Garner, and J.F. Dasta Hemodialysis of amikacin in critically ill patients Crit Care Med 16 1988 517 520
23. M. Kihara, Y. Ikeda, N. Takagi, H. Fujita, K. Shibata, and S. Masumori Pharmacokinetics of single-dose intravenous amikacin in critically ill patients undergoing slow hemodialysis Intensive Care Med 21 1995 348 351
24. L. Regeur, H. Colding, H. Jensen, and J.P. Kampmann Pharmacokinetics of amikacin during hemodialysis and peritoneal dialysis Antimicrob Agents Chemother 11 1977 214 218 (Pubitemid 8042469)
25. E. Armendariz, L. Chelluri, and R. Ptachcinski Pharmacokinetics of amikacin during continuous veno-venous hemofiltration Crit Care Med 18 1990 675 676 (Pubitemid 20185616)
26. B. Joos, M. Schmidli, and G. Keusch Pharmacokinetics of antimicrobial agents in anuric patients during continuous venovenous haemofiltration Nephrol Dial Transplant 11 1996 1582 1585 (Pubitemid 26252727)
27. Q. Tian, C.D. Gomersall, M. Ip, P.E. Tan, G.M. Joynt, and G.Y. Choi Adsorption of amikacin, a significant mechanism of elimination by hemofiltration Antimicrob Agents Chemother 52 2008 1009 1013 (Pubitemid 351358381)
28. G.L. Drusano, P.G. Ambrose, S.M. Bhavnani, J.S. Bertino, A.N. Nafziger, and A. Louie Back to the future: using aminoglycosides again and how to dose them optimally Clin Infect Dis 45 2007 753 760 (Pubitemid 47378891)
29. B. Layeux, F.S. Taccone, D. Fagnoul, J.L. Vincent, and F. Jacobs Amikacin monotherapy for sepsis caused by panresistant Pseudomonas aeruginosa Antimicrob Agents Chemother 54 2010 4939 4941
30. F. Bressolle, J.M. Kinowski, J.E. de la Coussaye, N. Wynn, J.J. Eledjam, and M. Galtier Clinical pharmacokinetics during continuous haemofiltration Clin Pharmacokinet 26 1994 457 471 (Pubitemid 24166335)
31. R.J. Tindula, P.J. Ambrose, and A.F. Harralson Aminoglycoside inactivation by penicillins and cephalosporins and its impact on drug-level monitoring Drug Intell Clin Pharm 17 1983 906 908 (Pubitemid 15156006)